Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome

Maurizio Averna, Luc Missault, Margus Viigimaa, Philippe Brudi, Arvind Shah, William Taggart, Qian Dong, Amy O. Johnson-Levonas, Helena Vaverkova, Michel Farnier

Risultato della ricerca: Article

8 Citazioni (Scopus)

Abstract

Metabolic syndrome (MetS) is a clustering of atherosclerotic coronary heart disease risk factors. This post-hoc analysis compared the effects of switching to ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg in a cohort of 618 high-risk hypercholesterolaemic patients with (n=368) and without (n=217) MetS who had previously been on statin monotherapy. Patients were randomised 1:1 to double-blind ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg for 6 weeks. Least squares mean percent change from baseline and 95% confidence intervals in lipid efficacy parameters were calculated for the population and within subgroups. Treatment with ezetimibe/simvastatin was significantly more effective than rosuvastatin at lowering low-density lipoprotein cholesterol, total cholesterol, non- high-density lipoprotein cholesterol, and apolipoprotein B (all p<0.001). No significant differences in treatment effects were seen between the presence and absence of MetS. In this post-hoc analysis of high-risk hypercholesterolaemic patients the lipid-reducing effects of ezetimibe/simvastatin or rosuvastatin were not altered significantly by the presence of MetS.
Lingua originaleEnglish
pagine (da-a)262-270
Numero di pagine9
RivistaDIABETES &amp; VASCULAR DISEASE RESEARCH
Volume8
Stato di pubblicazionePublished - 2011

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cita questo

Averna, M., Missault, L., Viigimaa, M., Brudi, P., Shah, A., Taggart, W., Dong, Q., Johnson-Levonas, A. O., Vaverkova, H., & Farnier, M. (2011). Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. DIABETES &amp; VASCULAR DISEASE RESEARCH, 8, 262-270.